Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Vyne Therapeutics Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 82.39m or 19,432.55% of revenues. In addition the company used 25.34m for operations while cash used for investing totalled 57.35m.
Cash flow per share | -0.9307 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.15 |
---|---|
Tangible book value per share | 5.15 |
More ▼
Balance sheet in USDView more
Current ratio | 7.13 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼